Skip to main content
OpenTrials
Completed

NCT Number: NCT01792843

Cognitive Phenotypes in Parkinson's Disease

* a data driven approach has identified different cognitive phenotypes in Parkinson's disease (PD) * this heterogeneity possibly reflects the diversity of the neuronal damage caused by the disease * we hypothesize that the different clinical presentations are associated to specific anatomical and functional correlates

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Maastricht University Medical Centre

Maastricht, Netherlands

About this study

Cognitive impairments are frequent in PD, even in non-demented patients. However, there is a substantial heterogeneity in the clinical presentation of cognitive deficits in PD 2 and also in their progression. This heterogeneity possibly reflects the diversity of the neuronal damage caused by the disease and recent studies suggest that these different clinical influence the risk of developing dementia.

Most studies on cognitive phenotypes in PD have used predefined categories, such as demented vs. non-demented, or PD-mild cognitive impairment vs. cognitively intact patients. However, such an approach may miss less obvious or unexpected presentations. To this end, in a first part of this study, we have used a data-driven approach (cluster analysis) to identify different cognitive phenotypes in PD. With such an approach where phenotypical profiles arise from the data without a priori assumptions, five cognitive presentations were identified: i°) cognitively intact patients (19.39%), ii°) patients with slight mental slowing and mild executive dysfunction (41.29%), iii°) patients with slightly impaired overall cognitive efficiency and deficits in all cognitive domains except recognition memory (12.93%), iv°) patients with severe mental slowing, impaired overall cognitive efficiency, and severe cognitive impairment in all domains, including memory (23.88%), and v°) patients with very severe impairment in all cognitive domains (2.51%). From these results, it could be hypothesized that cognitive deterioration in PD progresses along a continuum, with the exception of the fourth group that also exhibits memory deficits. This group may be characterized by a different underlying pathology, or comorbidity with Alzheimer's disease. The role of vascular factors has also to be considered.

The objectives of the current project are:

  • to validate the identified cognitive profiles prospectively in a new population using confirmatory cluster analysis.
  • to identify specific anatomical correlates for the identified cognitive profiles by magnetic resonance-imaging (MRI) scanning
  • to identify specific functional correlates of the identified cognitive profiles by high-density EEG (hd-EEG)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males or females;
  • 18 to 80 years;
  • Parkinson's disease, according to international criteria;
  • Without neurological co-morbidity;
  • Benefiting from health insurance;
  • Having read and understood the information form and having signed the consent form.

Exclusion criteria

  • Pregnant or breastfeeding women;
  • Parkinsonian syndrome other than PD;
  • Currently participating in an other clinical trial or study;
  • Patient whose physical or mental condition is incompatible with the study assessments;
  • Person under tutorship or curatorship;
  • Subjects with claustrophobia
  • Subjects carrying incompatible metallic devices such as pacemakers and certain mechanical valves
  • PD patients treated by deep brain stimulation

Treatment and study plan

data

Behavioral
  • comparisons of clinical characteristics
  • comparisons of cognitive profiles
  • comparisons of grey matter density patterns
  • comparisons of EEG rhythms features

Primary outcomes

  1. Frequency (%) of the cognitive profile

    Time frame: 2 years

    Frequency of the different observed cognitive profile, as coming from the cluster analysis

Secondary outcomes

  1. Grey matter density (voxels)

    Time frame: 2 years

    Grey matter density as measured by voxel-based morphometry

Other outcomes

  1. EEG power (microvolts2)

    Time frame: 2 years

    EEG power in the different frequency bands

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Registry information

Official study title

Cognitive Phenotypes in Parkinson's Disease: Anatomical and Functional Correlates

Acronym: CogPhenoPark

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Feb 15, 2013
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.